Findings

What do systematic reviews say?

2 questions · 4 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 50%High 2 · 50%

Irinotecan vs non‐irinotecan‐containing regimens

Progression‐free survival · people with advanced gastric cancer

Irinotecan leads to lower progression‐free survival compared with non‐irinotecan‐containing regimens (high certainty).

1 finding from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.76 [0.69, 0.84]
7 studies · 1640 participants
High

Irinotecan vs non‐irinotecan‐containing regimens

Progression‐free survival (PSF) · people with advanced gastric cancer

Irinotecan showed no clear difference in progression‐free survival ‐ Substitutive comparison compared with non‐irinotecan‐containing regimens (moderate certainty).

3 findings from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.85 [0.72, 1]
5 studies · 741 participants
Moderate
Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.51 [0.33, 0.77]
1 study · 90 participants
Moderate
Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.74 [0.66, 0.84]
2 studies · 809 participants
High